Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | The future for CAR T-cells in treating AML

Attilio Bondanza • 22 Jun 2017
EHA 2017
Acute Myeloid Leukemia Leukemia CAR-T

Attilio Bondanza, MD, PhD, from the San Raffaele Scientific Institute, Milano, Italy talks to us about a Phase I/II trial, which will take place in the future, investigating the effectiveness of using CAR T-cells to treat refractory acute myeloid leukemia, sponsored by the biotechnology company, MolMed. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.

More from Attilio Bondanza

1:37
Can we target AML with CAR T-cells?
Attilio Bondanza • 27 Jun 2017

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals